Parallax Volatility Advisers’s Viking Therapeutics VKTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-35,540
Closed -$942K 1833
2025
Q2
$942K Sell
35,540
-47,729
-57% -$1.26M ﹤0.01% 1071
2025
Q1
$2.01M Sell
83,269
-185,610
-69% -$5.87M 0.01% 867
2024
Q4
$10.8M Buy
+268,879
New +$15.3M 0.02% 543
2024
Q2
Sell
-16
Closed -$1.05K 2278
2024
Q1
$1.31K Buy
+16
New +$712 ﹤0.01% 1722
2023
Q2
Sell
-607
Closed -$12.7K 2894
2023
Q1
$10.1K Buy
+607
New +$6.27K ﹤0.01% 2394
2020
Q1
Sell
-44,000
Closed -$353K 2750
2019
Q4
$353K Buy
44,000
+5,333
+14% +$38.9K ﹤0.01% 1858
2019
Q3
$266K Sell
38,667
-10,809
-22% -$80.3K ﹤0.01% 1777
2019
Q2
$411K Sell
49,476
-41,868
-46% -$358K ﹤0.01% 1562
2019
Q1
$908K Buy
91,344
+64,132
+236% +$537K ﹤0.01% 1307
2018
Q4
$208K Buy
27,212
+14,213
+109% +$170K ﹤0.01% 1729
2018
Q3
$226K Buy
12,999
+10,406
+401% +$124K ﹤0.01% 1595
2018
Q2
$25K Sell
2,593
-4,881
-65% -$32.5K ﹤0.01% 1681
2018
Q1
$33K Hold
7,474
﹤0.01% 1639
2017
Q4
$30K Buy
+7,474
New +$21.7K ﹤0.01% 3494

Other funds holding VKTX

Parallax Volatility Advisers's VKTX Position: Q3 2025 in Review

Parallax Volatility Advisers sold out of Viking Therapeutics (VKTX) in Q3 2025, closing a stake of 35,540 shares — an estimated $942K sold.

Parallax Volatility Advisers first reported a position in VKTX in Q4 2017 and held it in 14 quarters. The position peaked at $10.8M in Q4 2024. 370 funds tracked by Wall St. Rank hold VKTX as of Q3 2025.

  • Parallax Volatility Advisers reported no remaining Viking Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Parallax Volatility Advisers sold 35,540 Viking Therapeutics shares in Q3 2025, an estimated $942K.
  • Parallax Volatility Advisers first reported a position in Viking Therapeutics in Q4 2017 and held it in 14 quarters.
  • Parallax Volatility Advisers's Viking Therapeutics position peaked at $10.8M in Q4 2024.
  • 370 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2025.

Based on Parallax Volatility Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.